Esbriet

Esbriet (pirfenidone) can improve survival rates of idiopathic pulmonary fibrosis (IPF) patients by 30 percent, a real-world retrospective analysis shows. The study, “Pirfenidone improves survival in IPF: results from a ... Read more

November 6, 2018November 9, 2018

No New Safety Concerns with Esbriet, Results from Long-term PASSPORT Study Show

Esbriet, News

Results from the long-term PASSPORT clinical study are consistent with the known safety profile of Esbriet (pirfenidone), further strengthening the safety of the therapy in patients with idiopathic pulmonary fibrosis ... Read more

October 12, 2018October 17, 2018

Analysis of Phase 3 Trial Data Shows Benefits of Esbriet for More Advanced IPF Patients

Esbriet, News

Treatment with Esbriet (pirfenidone) can effectively benefit patients with idiopathic pulmonary fibrosis (IPF) who have more advanced lung function impairment, by preventing a decline in exercise capacity and worsening ... Read more

September 28, 2018October 2, 2018

Esbriet and Ofev Show Significant Benefits in Real-Life Clinical Setting

Esbriet, News

Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib ... Read more

September 19, 2018September 24, 2018

Esbriet Enables Stable Lung Function Over 2 Years in IPF Patients, Real-World Study Confirms

Esbriet, News

Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) leads to stable lung function over two years, according to a real-world study. The data matches previous results from Phase ... Read more

September 18, 2018September 18, 2018

Nationwide Study Reveals Esbriet Use Patterns by PF Patients in Sweden

Esbriet, News

A comprehensive Swedish study reveals low use and lack of persistence with Esbriet (pirfenidone) treatment among patients with pulmonary fibrosis (PF). Results of this real-world study were presented in ... Read more

August 28, 2018September 4, 2018

Esbriet Dose Reductions Don’t Affect Its Potential to Manage IPF, Study Shows

Esbriet, News

Modifying the dose of Esbriet (pirfenidone) can effectively reduce the number of treatment-related adverse events without affecting the drug’s potential to manage idiopathic pulmonary fibrosis (IPF), a new retrospective ... Read more

August 7, 2018August 14, 2018

Ofev, Esbriet Combo Seen to Be Safe for IPF Patients in Phase 4 Trial

Esbriet, News

Adding Ofev (nintedanib) to Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF) is tolerated by most patients and has a similar safety profile as taking each medication alone, a Phase ... Read more

June 4, 2018June 4, 2018

France Foundation-Genentech Initiative to Improve IPF Diagnosis, Treatment at Local Level

Esbriet, News

Supported by an educational research grant from Genentech, the France Foundation is launching a mentoring and relationship-building program for community healthcare providers to improve how patients with idiopathic pulmonary fibrosis ... Read more

June 1, 2018June 1, 2018

New Lung-on-a-chip Technology Captures Fibrosis Progression and May Speed Treatment Discovery, Study Reports

Esbriet, News

A new lung-on-a-chip technology models the mechanical changes that occur in the lungs during idiopathic pulmonary fibrosis, possibly allowing for a faster and less expensive screening of potential new ... Read more

Esbriet

Esbriet Extends IPF Patient Survival, Real-world Study Reports

No New Safety Concerns with Esbriet, Results from Long-term PASSPORT Study Show

Analysis of Phase 3 Trial Data Shows Benefits of Esbriet for More Advanced IPF Patients

Esbriet and Ofev Show Significant Benefits in Real-Life Clinical Setting

Esbriet Enables Stable Lung Function Over 2 Years in IPF Patients, Real-World Study Confirms

Nationwide Study Reveals Esbriet Use Patterns by PF Patients in Sweden

Esbriet Dose Reductions Don’t Affect Its Potential to Manage IPF, Study Shows

Ofev, Esbriet Combo Seen to Be Safe for IPF Patients in Phase 4 Trial

France Foundation-Genentech Initiative to Improve IPF Diagnosis, Treatment at Local Level

New Lung-on-a-chip Technology Captures Fibrosis Progression and May Speed Treatment Discovery, Study Reports

Pin It on Pinterest